Gilead Lenacapavir cut HIV infections by 96% in trial

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

Gilead Lenacapavir cut **** infections by 96% in trial

A pharmacist holds a vial of lenacapavir, the new **** prevention injectable *****.

Nardus Engelbrecht | AP

Gilead‘s twice-yearly shot reduced **** infections by 96% in a second large study, the company said Thursday.

The positive phase three trial data on Lenacapavir sets the stage for likely approval by the U.S. Food and ***** Administration for **** prevention.

“Now that we have a comprehensive dataset across multiple study populations, Gilead will work urgently with regulatory, government, public health and community partners to ensure that, if approved, we can deliver twice-yearly lenacapavir for PrEP worldwide, for all those who want or need PrEP,” said Gilead CEO Daniel O’Day in a statement.

PrEP or, pre-exposure prophylaxis, is a medication taken to prevent getting ****, according to the Centers for ******** Control and Prevention.

Gilead shares climbed about 3% in premarket trading Thursday.

The company said 99.9% of participants who received Lenacapavir did not acquire ****, with two cases among 2,180 people. The trial included cisgender men, transgender men, transgender women and gender non-binary people who have **** with partners assigned male at birth.

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up

#Gilead #Lenacapavir #cut #**** #infections #trial

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up